Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Debt to Equity (2022 - 2025)

BioXcel Therapeutics has reported Debt to Equity over the past 4 years, most recently at -$1.15 for Q4 2025.

  • Quarterly results put Debt to Equity at -$1.15 for Q4 2025, down 4.27% from a year ago — trailing twelve months through Dec 2025 was -$1.15 (down 4.27% YoY), and the annual figure for FY2025 was -$1.15, down 4.27%.
  • Debt to Equity for Q4 2025 was -$1.15 at BioXcel Therapeutics, up from -$1.23 in the prior quarter.
  • Over the last five years, Debt to Equity for BTAI hit a ceiling of $16.66 in Q2 2023 and a floor of -$2.46 in Q3 2023.
  • Median Debt to Equity over the past 4 years was -$1.12 (2025), compared with a mean of $0.43.
  • Peak annual rise in Debt to Equity hit 623751.42% in 2023, while the deepest fall reached 439.44% in 2023.
  • BioXcel Therapeutics' Debt to Equity stood at $1.22 in 2022, then crashed by 246.22% to -$1.78 in 2023, then surged by 38.15% to -$1.1 in 2024, then dropped by 4.27% to -$1.15 in 2025.
  • The last three reported values for Debt to Equity were -$1.15 (Q4 2025), -$1.23 (Q3 2025), and -$1.01 (Q2 2025) per Business Quant data.